跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KIMMTRAK - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
KIMMTRAK
Authorized
STANDARD
KIMMTRAK
IMMUNOCORE IRELAND LIMITED
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c46672f8b99669ed
Company
IMMUNOCORE IRELAND LIMITED
Type
Standard
Approval Details
Approval Id
c46672f8b99669ed
Drug Approval Canada Name
KIMMTRAK
Product Name
KIMMTRAK
Status
Marketed
Status Date
2022-08-23
Original Market Date
2022-08-23
Din
02527588
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01XX75 TEBENTAFUSP
Atc Name
l 01 xx 75
Aig Number
0163721001
Company Name
IMMUNOCORE IRELAND LIMITED
Company Address
1, Sky Business Centres; Unit 21 Block Port Tunnel; Business Park, Clonshaugh, Dublin, --, Ireland, 17
Company Detail Path
/organization/immunocore-ireland-limited
Company Information
Pharmaceutical Company Name
IMMUNOCORE IRELAND LIMITED
Country Name
Ireland
City Name
dublin,country_ie
Address
UNIT 1, SKY BUSINESS CENTRES, UNIT 21 BLOCK PORT TUNNEL BUSINESS PARK
Active Ingredients
TEBENTAFUSP
100 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c46672f8b99669ed
Type
Standard
Back to Health Canada Approvals